Microsoft Advances AI-Driven Neurology Through INBRAIN Partnership
Microsoft's stock (NASDAQ:MSFT) climbed nearly 1.5% as the tech giant unveiled a collaboration with INBRAIN Neuroelectronics to develop next-generation brain-computer interfaces (BCIs). The partnership leverages Microsoft's agentic AI tools and Azure cloud platform to create adaptive neural therapies for conditions like Parkinson's disease and epilepsy.
INBRAIN's graphene-based neural technology, combined with Microsoft's AI ecosystem, aims to deliver real-time precision neurology. "This brings us closer to a future where brain disorders are treated with unprecedented accuracy," said INBRAIN CEO Carolina Aguilar. The initiative underscores Microsoft's strategic push into AI-powered healthcare solutions.